• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JVI: Alternative Recognition of the Conserved Stem-Epitope in Influenza A Hemagglutinin by a VH3-30-Encoded Heterosubtypic Antibody

tetano

Editor, Senior Moderator
Published ahead of print 9 April 2014, doi: 10.1128/JVI.00178-14 JVI.00178-14

Alternative Recognition of the Conserved Stem-Epitope in Influenza A Hemagglutinin by a VH3-30-Encoded Heterosubtypic Antibody.

Arkadiusz Wyrzuckia,
Cyrille Dreyfusb,
Ines Kohlera,
Marco Stecka,
Ian A. Wilsonb,c# and
Lars Hangartnera#

Institute of Medical Virology, University of Zurich, Winterthurerstrasse 190, 8057 Z?rich, Switzerlanda
Department of Integrative Structural and Computational Biology, The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, California, 92037, U.S.A.b
Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, U.S.A.c

ABSTRACT

A human monoclonal heterosubtypic antibody, mAb 3.1, with its heavy chain encoded by VH3-30, was isolated using phage display with immobilized hemagglutinin from A/Japan/305/1957(H2N2) as the target. Antibody 3.1 potently neutralizes influenza viruses from the H1a clade (i.e. H1, H2, H5, H6), but has little neutralizing activity against the H1b clade. Its crystal structure in complex with HA from a pandemic H1N1 influenza virus A/South Carolina/1/18(H1N1) revealed that, like other heterosubtypic anti-influenza antibodies, mAb3.1 contacts a hydrophobic groove in the HA stem, primarily using its heavy chain. However, in contrast to the closely related mAb FI6 that relies heavily on HCDR3 for binding, mAb 3.1 utilizes residues from HCDR1, HCDR3 and FR3. Interestingly, HCDR1 of mAb 3.1 adopts anα-helical conformation and engages in very similar hydrophobic interactions with the HA as the de novo in silico designed and affinity matured synthetic protein HB36.3. These findings improved our understanding of the molecular requirements for binding to the conserved epitope in the stem of the HA protein and, therefore, aid the development of more universal influenza vaccines targeting these epitopes.

Importance Influenza viruses rapidly evade pre-existing immunity by constantly altering the immunodominant neutralizing antibody epitopes (antigenic drift), or by acquiring new envelope serotypes (antigenic shift). As a consequence, the majority of antibodies elicited by immunization or infection only protect against the immunizing or closely related strains. Here, we describe a novel monoclonal antibody recognizing the conserved heterosubtypic epitope in the stem of influenza A virus hemagglutinin. This antibody, referred to as mAb 3.1, recognizes its epitope in a manner that resembles recognition of a similar epitope by the de novo in silico designed and affinity matured synthetic protein HB36.3. Thus, besides providing novel insights into the molecular interactions between heterosubtypic antibodies and influenza virus hemagglutinin, mAb 3.1 demonstrates that de novo in silico designed and affinity matured synthetic proteins can foretell naturally selected antibody binding. This knowledge will aid development of a pan-influenza vaccine.


http://jvi.asm.org/content/early/2014/04/03/JVI.00178-14.abstract
 
Back
Top Bottom